The DOI matches its Crossref record.
Interventions for bullous pemphigoid
Open accessAbstract
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Oral steroids are the standard treatment.This is an update of the review published in 2005. OBJECTIVES: To assess treatments for bullous pemphigoid. SEARCH STRATEGY: In August 2010 we updated our searches of the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (Clinical Trials), MEDLINE, EMBASE, and the Ongoing Trials registers. SELECTION CRITERIA: Randomised controlled trials of treatments for participants with immunofluorescence-confirmed bullous pemphigoid. DATA COLLECTION AND ANALYSIS: At least two authors evaluated the studies for the inclusion criteria, and extracted data independently. MAIN RESULTS: We included 10 randomised controlled trials (with a total of 1049 participants) of moderate to high risk of bias. All studies involved different comparisons, none had a placebo group. In 1 trial plasma exchange plus prednisone gave significantly better disease control at 1 month (0.3 mg/kg: RR 18.78, 95% CI 1.20 to 293.70) than prednisone alone (1.0 mg/kg: RR 1.79, 95% CI 1.11 to 2.90), while another trial showed no difference in disease control at 6 months.No differences in disease control were seen for different doses or formulations of prednisolone (one trial each), for azathioprine plus prednisone compared with prednisone alone (one trial), for prednisolone plus azathioprine compared with prednisolone plus plasma exchange (one trial), for prednisolone plus mycophenolate mofetil or plus azathioprine (one trial), for tetracycline plus nicotinamide compared with prednisolone (one trial). Chinese traditional medicine plus prednisone was not effective in one trial.There were no significant differences in healing in a comparison of a standard regimen of topical steroids (clobetasol) with a milder regimen (RR 1.00, 95% 0.97 to 1.03) in one trial. In another trial, clobetasol showed significantly more disease control than oral prednisolone in people with extensive and moderate disease (RR 1.09, 95% CI 1.02 to 1.17), with significantly reduced mortality and adverse events (RR 1.06, 95% CI 1.00 to 1.12). AUTHORS' CONCLUSIONS: Very potent topical steroids are effective and safe treatments for BP, but their use in extensive disease may be limited by side-effects and practical factors. Milder regimens (using lower doses of steroids) are safe and effective in moderate BP. Starting doses of prednisolone greater than 0.75 mg/kg/day do not give additional benefit, lower doses may be adequate to control disease and reduce the incidence and severity of adverse reactions. The effectiveness of adding plasma exchange, azathioprine or mycophenolate mofetil to corticosteroids, and combination treatment with tetracycline and nicotinamide needs further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Schmidt, E., & Zillikens, D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61140-4 · Cited by 1,015
Feliciani, C., Joly, P., Jonkman, M. F., Zambruno, G., Zillikens, D., Ioannides, D., Kowalewski, C., Jedlickova, H., Kárpáti, S., Marinovic, B., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13717 · Cited by 314
Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment
Bernard, P., & Antonicelli, F. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0264-2 · Cited by 257
Vitamins and photoaging: Do scientific data support their use?
Zussman, J., Ahdout, J., & Kim, J. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.07.037 · Cited by 74
Metadata
- Authors
- Kirtschig, G., Middleton, P., Bennett, C., Murrell, D. F., Wojnarowska, F., & Khumalo, N. P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-10-06
- Issue
- 10
- Pages
- CD002292-CD002292
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1939086364
- Cited by
- 188
- References
- 0
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interventions for bullous pemphigoid. https://app.cochat.ai/papers/10.1002/14651858.cd002292.pub3
- The paper
- Kirtschig, G., Middleton, P., Bennett, C., Murrell, D. F., Wojnarowska, F., & Khumalo, N. P. (2010). Interventions for bullous pemphigoid. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd002292.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.